28 November 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Holding in Company
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, was informed on 28 November 2019 that Mr Philippe Glatz now has a total interest in 15,659,162 ordinary shares of 25 pence each, equivalent to 6.42% of the Company's issued ordinary share capital.
Advanced Oncotherapy plc |
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO
|
|
|
|
Allenby Capital Limited (Nomad & Broker) |
|
Nick Athanas / Liz Kirchner / Nicholas Chambers
|
Tel: +44 (0) 20 7601 6100 |
|
|
FTI Consulting (Financial PR & IR) |
|
Simon Conway / Rob Winder |
Tel: +44 (0) 20 3727 1000 |
Notes for Editors
About Advanced Oncotherapy Plc - www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.